Comparative Pharmacology
Head-to-head clinical analysis: DIULO versus ENDURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIULO versus ENDURON.
DIULO vs ENDURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na+/Cl- symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased diuresis and decreased extracellular fluid volume.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
2.5 mg orally once daily, may increase to 5 mg once daily after 4 weeks if needed.
Oral, 2.5–5 mg once daily. Maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life is 1.5-2 hours (mean 1.8 h) in healthy adults; prolonged to 3-6 hours in renal impairment and up to 8 hours in severe heart failure.
Terminal elimination half-life: 24-48 hours (mean 36 hours); prolonged in renal impairment or heart failure, allowing once-daily dosing.
Primarily renal excretion (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 10-15% biliary/fecal elimination.
Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal (15-30%); dose adjustment required in renal impairment (CrCl <30 mL/min).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic